Novacyt SA (FRA:NYZ)
€ 0.566 0.005 (0.89%) Market Cap: 42.66 Mil Enterprise Value: 18.85 Mil PE Ratio: 0 PB Ratio: 0.50 GF Score: 42/100

Half Year 2023 Novacyt SA Investor webinar Transcript

Sep 28, 2023 / 11:30AM GMT
Release Date Price: €0.6735 (-9.35%)
Operator

Good afternoon, and welcome to the Novacyt Interim Results Investor Presentation. (Operator Instructions)

Before we begin, I'd like to submit the following poll. And for the benefit of those joining us from France, (foreign language).

I would now like to hand you over to James McCarthy. Good afternoon.

James Martin McCarthy;Steve Gibson
Novacyt S.A. - CFO, Acting CEO, Company Secretary & Director;Novacyt S.A. - Group

Thank you, [Alexandre]. Good afternoon, everybody. Welcome to the Novacyt half year results. I should just start by showing the disclaimer. And I'll just take that as read by everybody before we proceed.

Okay. So my name is James McCarthy. I'm the acting CEO of Novacyt since November last year, and prior to that, I've been almost 2 years as the CEO of the group. Delighted to be joined by Steve Gibson, who is the Finance Director; and Lyn Rees, who recently joined us from the Yourgene's acquisition. So perhaps if I ask those 2 gentlemen to introduce themselves before we proceed?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot